News
IMNN
0.5940
-5.56%
-0.0350
Imunon Earnings Call Highlights Clinical Progress Amid Funding Risk
TipRanks · 2d ago
Imunon price target lowered to $6 from $12 at Alliance Global
TipRanks · 3d ago
Imunon, Inc. Reports Third Quarter 2026 Financial Results and Provides Business Update
NASDAQ · 4d ago
Imunon Q3 2026 Earnings Call Transcript
Benzinga · 4d ago
Imunon, Inc. Loss At -$3.813 Mln In Q3
NASDAQ · 4d ago
Imunon GAAP EPS of -$0.64 misses by $0.06
Seeking Alpha · 4d ago
Imunon Q3 EPS $(0.64) Misses $(0.55) Estimate
Benzinga · 4d ago
Here are the major earnings before the open Thursday
Seeking Alpha · 5d ago
Weekly Report: what happened at IMNN last week (1102-1106)?
Weekly Report · 11/09 09:59
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 11/04 12:05
Weekly Report: what happened at IMNN last week (1026-1030)?
Weekly Report · 11/02 09:59
Imunon: Strengthening IL-12 Validation and Clinical Momentum Support Unchanged $10 Price Target and Buy Rating
TipRanks · 10/29 23:05
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 10/27 17:05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 10/27 12:05
Imunon Updates Investor Presentation for Upcoming Engagements
TipRanks · 10/27 10:31
Imunon files to sell 20M shares of common stock, pre-funded warrants
TipRanks · 10/27 10:30
Weekly Report: what happened at IMNN last week (1019-1023)?
Weekly Report · 10/26 09:59
Imunon Divests ThermoDox Assets to VoxelDox Therapeutics
TipRanks · 10/21 12:48
IMUNON To Sell ThermoDox Rights To VoxelDox For Glioblastoma Multiforme
NASDAQ · 10/21 12:42
Imunon to sell ThermoDox rights to VoxelDox Therapeutics for ownership stake
TipRanks · 10/21 12:26
More
Webull provides a variety of real-time IMNN stock news. You can receive the latest news about Imunon Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMNN
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.